gavi.org
HEXAVALENT INVESTMENT
CASE
BOARD MEETING
Aur?lia Nguyen, Kate O?Brien
26 -27 June 2023, Geneva, Switzerland
Governance pathway and key decisions
Board approved:
? In -principle support for wP -Hexavalent , subject to a vaccine being licensed, recommended for use by WHO, WHO
prequalified, and with market attributes met that support the successful implementation
? Support for IPV -based on the rationale that polio eradication is a global public health good, and routine vaccination
with IPV plays a fundamental role in the polio eradication strategy
Gavi Alliance partners assessed Hexavalent support conditions , using price and supply information ? 4/5 conditions met,
price condition to be confirmed by MSDC
MSDC (February 2023) confirmed that the price aligns with Hexavalent?s expected benefits ? 5/5 support conditions are met
PPC (May 2023) recommended to the Board to open a funding window for Hexavalent in Q3 2023
Board (June 2023) to decide on opening a funding window for Hexavalent in Q3 2023
2018
2022
2023
2019
Gavi joined GPEI as an official core partner
Board approved : continuation of its 2019 IPV support decision -countries are exempt from Gavi eligibility and co -financing
policies until polio eradication and the withdrawal of bivalent oral polio vaccine (bOPV ) from routine immunisation
Board Meeting, 26 -27 June 2023 2

gavi.org
COVAX UPDATE AND GAVI?S ROLE IN A FUTURE COVID -19
VACCINE PROGRAMME
BOARD MEETING
Derrick Sim, Richard Mihigo
26 -2 7 June 2023, Geneva, Switzerland
Population
Focus
Progression from COVAX to Gavi -supported COVID -19 programme
Today: COVAX in transition
2024 -2025: Potential Gavi
supported COVID -19 Programme
Increasing focus on high
priority user groups, incl.
additional boosters
Continued support across all
user groups for primary + 1, esp.
for low coverage countries
Transition to support high
priority user groups
Additional doses/ newer products
via Pandemic Vaccine Pool (PVP)
for worst case scenario
Reactive strategy for worst
case scenario
ILLUSTRATIVE
2 Board Meeting, 26 -27 June 2023
2026 and beyond
To be evaluated through the
Vaccine Investment Strategy

gavi.org
GAVI?S ROLE IN PANDEMIC PREVENTION,
PREPAREDNESS AND RESPONSE
Board Meeting
Derrick Sim, David Kinder
26 -27 June 2023, Geneva, Switzerland
Gavi?s Role in PPPR
2
? Outbreak Response and Prevention
? Vaccine Stockpiles
? Market Shaping for Manufacturing
Diversification
? Financial Innovation
? Health System Strengthening
? COVAX
1. Retaining and enhancing capabilities for readiness and response
? Global Virtual Pooled Inventory accelerates access to vaccines for
emerging / rare diseases
? Health Care Worker programme protects capabilities for response
? 'Playbook' for Surge and Operational Capabilities
2. Resilient Health Care Systems and Routine Immunisation (RI)
programmes
? Digital Health Tools strengthen resilience of country health care systems,
RI, vaccine traceability
? Resilience and adaptability to Climate Emergency challenge
3. Diversification of Regional Manufacturing
? African Manufacturing ?4 Pillar? Strategy
4. Financial innovation
? Day Zero Financing Facility
Emerging Key Areas for an Alliance Plan for PPPR Vaccines are critical in outbreaks,
epidemics, pandemics
Alliance is the hub for vaccines and vaccines
delivery in global health architecture
Gavi has brought capabilities & contributed
to PPPR as part of its core activities:
Board Meeting, 26 -27 June 2023

gavi.org
VACCINE INVESTMENT
STRATEGY 2024
BOARD MEETING
Marta Tufet Bayona
26 -27 June 2023, Geneva, Switzerland
Vaccine Investment Strategy informs Gavi 6.0 (2026 ? 2030)
Evidence -based approach to identify immunisation investments for future strategic
cycle(s), while sending valuable advance signals to vaccine developers and suppliers
Transparent
methodology
Analytic review of
evidence & modelling
Consultations and
independent expert
advice
Every 5 years
Strategic decision -making
Predictability for long -term
planning by industry,
governments & donors
? Gavi strategy
? Resource mobilisation
? Vaccine programmes
? Global stockpiles
? Learning agendas
In response to public health threat or a research and development (R&D) milestone for a priority pathogen,
diseases of epidemic/pandemic potential can be evaluated in real time, outside five -year cycle, through VIS epidemics framework.
Informs:
Types of investment:
2 Board Meeting, 26 -27 June 2023

gavi.org
COUNTRY PROGRAMMES
DELIVERY PRESENTATION
BOARD MEETING
Thabani Maphosa, Ephrem Lemango ,
Kate O?Brien
26 -27 June 2023, Geneva, Switzerland
Planning &
Execution

Classified as Internal
HPV vaccination
Experience of Burkina
Faso
Minister Kargougou J.L.C Robert
Gavi Board Meeting
June 2023
Classified as Internal
Context of HPV vaccination
Security Context
? 200 Health
Facilities closed or
with limited
functionning
? IDPs
? 316 245 nine years
girls
Epidemiology of
Cervical cancer
(Globocan 2020)
? 1 132 new cases
? Incidence of CCU
20/100.000 women
? Mortality of 11/100
000
Challenges exists but we are resilient!

Classified as Internal
Vaccination contre le
papillomavirus
Exp?rience du
Burkina Faso
Kargougou J.L.C Robert, Ministre de la sant ?
Burkin a Faso
June 2023
Classified as Internal
Contexte de la vaccination contre le papillomavirus
Contexte s?curitaire
? 200 CSPS ferm?s ou
fonctionnant ?
minima
? Personnes
d?plac?es interne
? 316 245 filles de
neuf ans
Cancer du col de
l? uterus au BFA
(Globocan 2020)
? 1132 nouveau
cas/an
? Incidence :
20/100.000 femme
? Mortalit? :
11/100.000
Les d?fis existent, mais nous sommes r?silients !

gavi.org
CONSENT AGENDA
BOARD MEETING
26 -27 June 2023, Geneva, Switzerland
Decision 1: Consent Agenda: Board and Committee
appointments
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:
a) Appoint Sai Prasad as Board Member representing the vaccine industry developing countries in the seat
currently held by Mahima Datla effective 1 July 2023 and until 30 June 2026
b) Reappoint Beth Arthy as Board Member representing the United Kingdom on the donor constituency
cluster anchored by the United Kingdom, effective 1 September 2023 and until 31 August 2024
c) Reappoint the following to the Market -Sensitive Decisions Committee and to the Programme and Policy
Committee effective immediately:
? Beth Arthy (Board Member) until 31 December 2023
d) Appoint the following to the Governance Committee effective 1 July 2023:
? Sai Prasad (Board Member) until 31 December 2023
e) Appoint the following to the Audit and Finance Committee effective 1 July 2023:
? Deena Shiff (Board Member) until 31 December 2023
f) Appoint the following to the Investment Committee effective 1 July 2023:
? Sai Prasad (Board Member) until 31 December 2023
? Teresa Ressel (Board Member) until 31 December 2023
2 Board Meeting, 26 -27 June 2023

gavi.org
CEO Board
Update
D R S E T H B E R K L E Y
2 CEO Board Update
? >20 heads of state and ministers , plus private sector
innovators, civil society, pharmaceutical industry
? New pledge from Republic of Korea
? European Investment Bank (EIB) support extended
? New partnerships with private sector, philanthropy and
development finance ? many through Gavi Matching Fund
? MTR report: Alliance on track to meet majority of key
commitments to donors
Mid - Term Review conference hosted by Spain

1


Board -2023 -Mtg -02-Evaluation Advisory Committee Chair Report
Report to the Board
26 -27 June 2023

Subject Evaluation Advisory Committee Chair Report
Category For Information
Section A: Introduction
? This report provides the Board with an overview of the activities of, and
guidance provided by, the Evaluation Advisory Committee (EAC) since the
Committee Chair last reported to the Board in December 2022.
? At the in -person EAC meeting on 22 -23 March 2023, the EAC provided
guidance on: (i) the approach to assessing partners? role s across the Alliance
Strategy in evaluation s; (ii) the COVAX Facility and COVAX Advance Market
Commitment (AMC) Formative Review and Baseline Study; (iii) the proposed
scope, approach, and key questions of the next phase of the COVAX Facility
and COVAX AMC evaluation; (iv) progress of the commissio ned Gavi 5. 1
centralised evaluations; (v) the Zero -Dose learning agenda and related ongoing
evaluation; (vi) the operationali sation of the changes to the Gavi Evaluation
Policy; and (vii) EAC engagement in Gavi 5. 1 evaluations.
? Overarching issues and guidance
? As reported at previous Board meetings, the EAC continues to reflect on its
Remit, Voice and Practice in supporting a G avi evaluation portfolio of optimal
Independence, Credibility and Utility. The Multilateral Organisation
Performance Assess ment Network (MOPAN ) assessment, a potential further
independent assessment of the Evaluation function, and planning for Gavi 6.0
all offer opportunities to support this work.
? Recogni sing the importance of partnerships given the nature of Gavi as an
Allia nce, EAC members advised that Gavi Alliance partners should be
considered within the scope of the evaluations where their roles, responsibilities
and delivery contributes to the area of Gavi's work or Theory of Change (ToC)
being evaluated, and the focus f or evaluations should be on learning rather than
accountability of specific partners. The discussion focused on: (i) developing
and promoting an approach to enhanced engagement with partners on the
scope and questions for evaluations, to promote shared own ership of findings
and recommendations; and (ii) ensuring independent evaluators undertaking
evaluations are well briefed on the Gavi Alliance model and on the assumptions
related to the roles and responsibilities of partners within the ToC being
evaluated . The EAC further advised that the latter should be conducted as part
of the inception process - rather than as a condition of bidding - and validated
by relevant Alliance stakeholders.
? The EAC reviewed findings from an After Action Review on the
operati onali sation of the changes to the Gavi Evaluation Policy which was
revised in December 2021 to allow EAC members to join Evaluation Steering

1


Board -2023 -Mtg -02-Governance Committee Chair Report
Report to the Board
26 -27 June 2023

Subject Governance Committee Chair Report
Category For Information
Section A: Introduction
? This report provides the Board with an overview of the activities of the
Governance Committee ( GC ) since the Committee Chair last reported to the
Board in December 2022 .
? The GC met virtually on 9 February 2023, met in person on 29 March 2023 and
will meet again virtually on 22 June 2023 .
? In addition to some business such as Board and Committee nominations , the
recruitment of Unaffiliated Board Members and the governance risk matrix ,
Committee discussions focused on work in relation to (i) the CEO recruitment
process , appointment and transition ; (ii) the Board and Committee Evaluation;
(iii) updates on Operational Excellence and Human Resources; (iv) updates to
the Board Travel and Delegation of Authority policies ; and (v) guidelines for the
dissemination of Board and Committee materials and draft confidentiality
undertaki ng for Board and Committee Members .
? At its meeting on 22 June 2023 the Governance Committee will discuss the
nomination process for a Vice Chair to succeed Sarah Gou lding who comes to
the end of her second term on 31 De cember 2023 .
? The GC C hair report is attached in the form of a presentation as Annex A .
Annexes
Annex A : Governance Committee Chair report

1 Board-2023-Mtg-02-Investment Committee Chair Report
Report to the Board
26-27 June 2023
Subject Investment Committee Chair Report
Category For Information
Section A: Introduction
? This report provides the Board with an overview of the activities of the
Investment Committee since the Committee Chair last reported to the Board in
December 2022 .
? The total portfolio value is US$ 1.2 billion. The re is US$ 17 million of cash
out side of the long- term portfolio with Gavi?s Swiss custodian available for
immediate investment.
? The financial markets experienced market volatility across equity and fixed
income markets but still had positive gains year -to -date after brutal
performance last year. Since the end of 2022, US headline inflation steadily
declined from 6.5% to the current 4. 0% (end of May ). This decline ignited a
significant run-up by growth stocks . To show the scale of outperformance, the
tech- heavy Nasdaq 100 Index returned 21.4% vs S&P 500?s return of 9.2% as
of the end of April, and the trend continues. The inflation rate, while falling,
remains above central bank targets .
?T

he increase in interest rates sparked market instability with the failure or an
orderly winddown of several US banks. Gavi?s long- term portfolio suffered
minimal impact and the Investments team reported the impact to the Investment
Committee and the senior management team.
? The long- term portfolio had a year -to -date return of +3.9% versus the policy
benchmark return of +4.6% as of 30 April 2023. Gavi?s Equity and Diversifiers
assets contributed to the year -to -date portfolio underperformance. The Fixed
Income assets modestly outperformed its composite benchmark. For trailing 1
year, 3 years? and 5 years? annualised periods, the long- term portfolio
outperformed its policy index.
? The Equity composite underperformed with a return of +6.5% versus its
benchmark return of +8.3%. A long- short technology-focused fund and a
market -neutral strategy were the main contributors to the equity
underperformance. The former has been terminated for underperformance. A
growth equity fund with a focus on shareholder engagement and a US index
fund were significant outperformers relative to the composite benchmark.
? T

he Diversifiers composite underperformed with a return of - 0.7% versus its
benchmark return of +1.0%. A ?9.3% return from a systematic trend -following
strategy contributed significantly to the underperformance. This fund had a
substantial risk allocation to higher interest rates and the drop in global yields
during March?s banking turmoil hurt their performance. The manager of the fund